ESMO2022 focuses on the therapeutic benefits of androgen receptor antagonists for mHSPC from a patient perspective

*For medical professionals only

Effectively improving patients' disease symptoms and quality of life is also an important mission of anti-cancer treatment!

Advanced prostate cancer can be divided into several different stages, of which metastatic hormone-sensitive prostate cancer (mHSPC) refers to patients who still respond to androgen deprivation therapy (ADT), and effective treatment in the mHSPC stage delays the patient's progression to the castration refractory stage (mCRPC), which is important

Professor Bertrand Tombal of the Catholic University of Leuven, Belgium, introduced the quality of life and patient-related endpoints in ARASENS, a key clinical phase III study of darotamide in the treatment of mHSPC patients

Focus on the unmet clinical needs of mHSPC patients

Erik Briers, Vice President of Europa Uomo, a well-known European prostate cancer patient organization, introduced the unmet treatment needs of mHSPC patients from the patient's point of view, and on the whole, mHSPC patients have three major needs for clinical treatment, namely: prolonging survival, delaying progress to mCRPC and maintaining quality of

How to truly transform the outcome of mHSPC? Experts have something to say

In the online discussion session of the conference, the participating experts and representatives of patient organizations carried out a wonderful discussion on the topic of "transforming the outcome of prostate cancer" and reached the following agreements: 1.

[1] Fizazi K,Shore N,Tammela T L,et al.

[2] Smith M R,Hussain M,Saad F,et al.

[3] Venderbos L D F,Deschamps A,Dowling J,et al.

*This article is for the sole purpose of providing scientific information to medical professionals and does not represent the views of this platform